DE69227627T2 - Alifatische Propargylamine als selektive MAO-B Inhibitoren und als Neuroprotektive Agenzien - Google Patents

Alifatische Propargylamine als selektive MAO-B Inhibitoren und als Neuroprotektive Agenzien

Info

Publication number
DE69227627T2
DE69227627T2 DE69227627T DE69227627T DE69227627T2 DE 69227627 T2 DE69227627 T2 DE 69227627T2 DE 69227627 T DE69227627 T DE 69227627T DE 69227627 T DE69227627 T DE 69227627T DE 69227627 T2 DE69227627 T2 DE 69227627T2
Authority
DE
Germany
Prior art keywords
pct
propargylamines
inhibitors
sec
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69227627T
Other languages
English (en)
Other versions
DE69227627D1 (de
Inventor
Peter Yu
Bruce Davis
Alan Boulton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Saskatchewan
Original Assignee
University of Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Saskatchewan filed Critical University of Saskatchewan
Application granted granted Critical
Publication of DE69227627D1 publication Critical patent/DE69227627D1/de
Publication of DE69227627T2 publication Critical patent/DE69227627T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/20Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C07C211/23Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton the carbon skeleton containing carbon-to-carbon triple bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69227627T 1991-03-01 1992-02-28 Alifatische Propargylamine als selektive MAO-B Inhibitoren und als Neuroprotektive Agenzien Expired - Fee Related DE69227627T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/663,018 US5169868A (en) 1991-03-01 1991-03-01 Aliphatic propargylamines as specific mao-b inhibitors
PCT/CA1992/000090 WO1992015551A1 (en) 1991-03-01 1992-02-28 Aliphatic propargylamines as selective mao-b inhibitors and as neuroprotective agents

Publications (2)

Publication Number Publication Date
DE69227627D1 DE69227627D1 (de) 1998-12-24
DE69227627T2 true DE69227627T2 (de) 1999-06-24

Family

ID=24660178

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227627T Expired - Fee Related DE69227627T2 (de) 1991-03-01 1992-02-28 Alifatische Propargylamine als selektive MAO-B Inhibitoren und als Neuroprotektive Agenzien

Country Status (8)

Country Link
US (2) US5169868A (de)
EP (1) EP0573498B1 (de)
JP (1) JP3129733B2 (de)
AT (1) ATE173459T1 (de)
AU (1) AU658611B2 (de)
CA (1) CA2105171A1 (de)
DE (1) DE69227627T2 (de)
WO (1) WO1992015551A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
ES2149850T3 (es) * 1993-05-04 2000-11-16 Ceva Sante Animale Utilizacion de la selegilina en medicina veterinaria.
CA2180841C (en) * 1994-01-10 2007-03-27 Sasson Cohen 1-aminoindan derivatives and compositions thereof
DE19708461A1 (de) * 1997-02-18 1998-08-27 Meulen Volker Prof Dr Ter Verwendung aminerg wirkender Substanzen zur Herstellung eines Arzneimittels für die Behandlung viraler Infektionen des zentralen Nervensystems
US6111108A (en) * 1997-07-01 2000-08-29 Midwest Research Institute Extraction of biologically active components from Camptotheca acuminata with supercritical fluids
US5840979A (en) * 1997-07-14 1998-11-24 University Of Saskatchewan Aliphatic propargylamines as cellular rescue agents
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
DE69902748T2 (de) * 1998-01-13 2003-08-07 Univ Saskatchewan Propargylamin enthaltende zusammensetzung zur verbesserung der krebstherapie
US6809120B1 (en) 1998-01-13 2004-10-26 University Of Saskatchewan Technologies Inc. Composition containing propargylamine for enhancing cancer therapy
ATE375975T1 (de) * 1998-03-26 2007-11-15 Univ Saskatchewan Aliphatische aminosäure und aminophosphonsäure, aminonitrile und aminotetrazole als zellulares rettungsmittel
US6984754B1 (en) 1998-03-26 2006-01-10 University Of Saskatchewan Technologies Inc. Aliphatic amino carboxylic and amino phosphonic acids amino nitriles and amino tetrazoles as cellular rescue agents
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
US20040062787A1 (en) * 2001-12-17 2004-04-01 Daley William Lionel Therapeutic combination of amlodipineand benazepril/benazeprilat
US8058442B2 (en) * 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
WO2005051371A1 (en) * 2003-11-25 2005-06-09 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
WO2007016361A2 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
EP2053033A1 (de) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Verbindungen zur Verwendung bei der Abbildung, Diagnose und/oder Behandlung von Erkrankungen des zentralen Nervensystems oder von Tumoren
EP2309858A4 (de) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen
KR101619564B1 (ko) * 2009-04-23 2016-05-10 바이엘 파마 악티엔게젤샤프트 F-18 표지 pet 추적자에 관한 신규 전구체 분자
TR201909277T4 (tr) 2010-02-03 2019-07-22 Pharma Two B Ltd Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
EP2621490A4 (de) 2010-09-29 2014-04-02 Teva Pharma Propargyl-trifluormethoxy-aminobenzothiazolderivate sowie ihre herstellung und verwendung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB342651A (en) * 1929-10-03 1931-02-03 British Celanese Improvements in the manufacture of artificial filaments, threads & the like by wet spinning methods
GB842651A (en) * 1957-04-01 1960-07-27 Lakeside Lab Inc Novel acetylene compounds and process of preparing same
BE576562A (fr) * 1958-03-21 1959-07-01 Armour & Co Solution stabilisée de chymotrypsine
US3000903A (en) * 1959-09-15 1961-09-19 Lakeside Lab Inc Phenylalkylhydrazines and use as psychotherapeutics
US2997442A (en) * 1960-03-30 1961-08-22 Louise F Peale Lubricating oil composition
FR1453844A (fr) * 1965-03-19 1966-07-22 Soc Ind Fab Antibiotiques Sifa Nouvelles n-propynyl alcoylamines et leurs sels et procédé de préparation
US4201725A (en) * 1974-05-20 1980-05-06 Labaz Secondary amines
US4650907A (en) * 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
JPH03176457A (ja) * 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材

Also Published As

Publication number Publication date
AU658611B2 (en) 1995-04-27
AU1323692A (en) 1992-10-06
JP3129733B2 (ja) 2001-01-31
JPH06505241A (ja) 1994-06-16
EP0573498A1 (de) 1993-12-15
EP0573498B1 (de) 1998-11-18
WO1992015551A1 (en) 1992-09-17
US5508311A (en) 1996-04-16
DE69227627D1 (de) 1998-12-24
ATE173459T1 (de) 1998-12-15
US5169868A (en) 1992-12-08
CA2105171A1 (en) 1992-09-02

Similar Documents

Publication Publication Date Title
ATE173459T1 (de) Alifatische propargylamine als selektive mao-b inhibitoren und als neuroprotektive agenzien
NO20013379D0 (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
NO308739B1 (no) Imidazolderivater samt medisinsk sammensetning og anti-HIV- sammensetning omfattende samme
HUP0102453A2 (hu) Adenozinszármazékok, alkalmazásuk és e vegyületeket tartalmazó gyógyászati készítmények
DK1424330T3 (da) Aktivator for peroxisom proliferator-responsiv receptor delta
ES2137169T3 (es) Nuevos derivados de tiazolilbenzofurano, procedimientos para su preparacion y composicion farmaceutica que los contiene.
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
PT1468692E (pt) Utilizacao de 2,6-dialquil-4-sililfenois para o tratamento do xantoma
IT1196423B (it) Benzotiazolin-composti
CS183791A3 (en) Derivatives of 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanes, process for their preparation and their therapeutical application
DK1471059T3 (da) 2,4,6-tris(dineopentyl-4'-aminobenzalmalonat)-s-triazin, fotobeskyttende kosmetiske sammensætninger indeholdende denne forbindelse og anvendelse af den nævnte forbindelse
SE8303913D0 (sv) Heterocykliska foreningar
DK0609281T3 (da) Benzoxazol-, benzothiazol- og benzimidazol-derivater til anvendelse som fungicider
ES2190781T3 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
ES2140393T3 (es) Compuestos de penem.
PT100682A (pt) Agentes anti-helminticos derivados de benzimidazole e processo para a sua preparacao
WO2000024389A3 (en) Benzoquinoline derivatives useful as antibacterial agents
DE69521895D1 (de) Indolderivate als prodrugs von "5-ht1-like" rezeptor agonisten
HUP0203455A2 (hu) 2-Arilkinolin-származékok, a vegyületek előállítása és gyógyászati készítményekben való alkalmazása
ES2158809A1 (es) Nuevos derivados sulfonados como inhibidores de la ciclooxigenasa ii.
KR950704243A (ko) 아세트아미드 유도체(acetamide derivative)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee